➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Harvard Business School
Merck
Colorcon
Mallinckrodt

Last Updated: September 22, 2021

DrugPatentWatch Database Preview

Claims for Patent: 5,610,043

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 5,610,043
Title: Human prostatic cell lines immortalized by adenovirus 12-simian virus 40 (AD12/SV40) hybrid virus
Abstract:Immortalized non-tumorigenic or tumorigenic human prostatic epithelial and fibroblast cell lines and derivatives thereof, containing DNA of a hybrid virus between adenovirus 12 and simian virus 40. The cell lines are useful for research on causes, treatment and prevention of prostate cancer, benign prostatic hyperplasia, male infertility, birth defects, aging and assessment of environmental toxic agents.
Inventor(s): Webber; Mukta M. (Eagle, MI), Rhim; Johng S. (Potomac, MD)
Assignee: The United States of America as represented by the Department of Health (Washington, DC)
Application Number:08/234,981
Patent Claims:1. An immortalized adult human normal prostatic epithelial or fibroblast cell derived cell line free of other cell lines and containing DNA of adenovirus and simian virus 40 as a hybrid virus, the cell line having the identifying characteristics of the prostatic epithelial or fibroblast cell without the hybrid virus in addition to being immortalized by the hybrid virus.

2. The cell line of claim 1 wherein the simian virus 40 is deposited as ATCC VR-239.

3. The cell line of claim 1 wherein the adenovirus is adenovirus 12 deposited as ATCC VR-863.

4. The cell line of claim 1 wherein the adenovirus is adenovirus 12 and the simian virus 40 is deposited as ATCC VR-863 and VR-239, respectively.

5. The cell line of claim 1 which produces prostate specific antigen.

6. A cell line deposited as ATCC CRL 11611.

7. An immortalized human prostatic epithelial cell line wherein the cell line has the phenotypic characteristics comprising: cytokeratins 8/18 positive, desmin negative, Factor VIII negative, contact inhibited, anchorage dependent, androgen responsive, plasminogen activator secretion normal, collagenase secretion normal, is non-tumorigenic, produces prostate specific antigen and contains a hybrid virus of adenovirus and simian virus 40.

8. The cell line of claim 7 wherein the simian virus 40 is deposited as ATCC VR-239 and the adenovirus is adenovirus 12 deposited as ATCC VR-863.

9. A kit for screening a carcinogenic, chemotherapeutic, chemopreventive, anti-invasive, anti-metastatic or anti-angiogenic agent comprising an immortalized adult human prostatic epithelial cell derived cell line containing DNA of adenovirus and simian virus 40 as a hybrid virus, the cell line having the identifying characteristics of the prostatic epithelial cell without the hybrid virus in addition to being immortalized by the hybrid virus.

10. The kit according to claim 9 wherein the immortalized cell line is immortalized using simian virus 40 deposited as ATCC VR-239 and adenovirus 12 deposited as ATCC VR-863.

11. The kit according to claim 9 wherein the immortalized cell line is non-tumorigenic.

12. The kit according to claim 9 wherein the immortalized cell line is made tumorigenic after additional transformation by infection with oncogenic viruses, activation of oncogenes, transfection with activated oncogenes, loss of suppressor genes, or chemical exposure or radiation.

13. The kit of claim 9 wherein the cell line produces prostate specific antigen.

14. A method for producing an immortalized adult human normal prostatic epithelial or fibroblast cell derived cell line which comprises:

(a) providing non-malignant human prostatic epithelial or fibroblast cells in a medium; and

(b) infecting the human prostatic epithelial or fibroblast cells in the medium with DNA from adenovirus and simian virus 40 as a hybrid virus to thereby immortalize the cells with the hybrid virus to produce the cell line, wherein the cell line has the identifying characteristics of the prostatic epithelial or fibroblast cell without the hybrid virus in addition to being immortalized by the hybrid virus.

15. The method of claim 14 wherein the simian virus 40 is deposited as ATCC VR-239.

16. The method of claim 14 wherein the adenovirus is adenovirus 12 deposited as ATCC VR-863.

17. The method of claim 14 wherein the adenovirus is adenovirus 12 and the simian virus 40 is deposited as ATCC VR-863 and VR-239, respectively.

18. The method of claim 14 wherein the immortalized cell line deposited as ATCC CRL 11611.

19. The method of claim 14 wherein after the infecting in step (b) the cell line is subjected to multiple cloning to select a non-virus producing cell line in a serum free, chemically defined medium.

20. The method of claim 19 wherein the medium contains pituitary extract and epidermal growth factor.

21. The method of claim 14 wherein the cell line produces prostate specific antigen.

Details for Patent 5,610,043

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04 ⤷  Free Forever Trial The United States of America as represented by the Department of Health (Washington, DC) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
McKinsey
McKesson
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.